Phase 2 Readout
KYMR: Phase 2 Readout: kt-621
December 31, 2026 · kt-621. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- Kymera Therapeutics, Inc. (KYMR)
- Drug
- kt-621
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout~quarter
Phase 2 Readout: kt-621
- Drug
- kt-621
- Indication
- moderate to severe atopic dermatitis